DRONABINOL ENHANCES APPETITE AND CONTROLS WEIGHT LOSS IN HIV PATIENTS (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

DRONABINOL ENHANCES APPETITE AND CONTROLS WEIGHT LOSS IN HIV PATIENTS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A9 1991. Unique Identifier : AIDSLINE ICDB/91671491
Conant M; Roy D; Shepard KV; Plasse TF; Univ. of California, San Francisco, CA 94115

Abstract: Dronabinol, delta-9-THC in sesame oil (Marinol, Roxane Laboratories, Columbus, OH) has been noted in a past study to cause wt gain in HIV patients (pts). To date 19 symptomatic HIV pts with a history of loss of greater than 5% total body wt over 3 mo prior to study entry have been treated. This is an open, dose-ranging study; pt accrual is continuing. After a 1-wk observation period, pts received dronabinol daily for 4 wk. Appetite was measured before each meal and mood once daily on a 100 mm visual analog scale. Pts were considered evaluable if they received at least 2 wk of dronabinol. Three pts (1 each at 2.5 bid, 2.5 tid and 5 bid) discontinued due to intercurrent illness; 5 (4 at 2.5 tid and 1 at 5 bid) due to moderate but persistent high, and 1 each (2.5 tid) due to moderate paranoid feelings and severe vomiting possibly related to study medication; side effects subsided within hours upon discontinuation of treatment. Results are presented in a table. Dosing bid (before lunch and dinner) was well tolerated. Of 11 evaluable pts, 4 gained wt and 6 lost wt less rapidly when on dronabinol than before treatment; all but 2 pts noted improvement in appetite and mood.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/PHYSIOPATHOLOGY/ PSYCHOLOGY Affect/DRUG EFFECTS Appetite/*DRUG EFFECTS Drug Administration Schedule Human Hunger/DRUG EFFECTS HIV Infections/*DRUG THERAPY/PHYSIOPATHOLOGY/PSYCHOLOGY Tetrahydrocannabinol/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Weight Loss/*DRUG EFFECTS ABSTRACT
910930
M9190739

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .